Market research
ECX.F Epigenomics AG
F EUR Healthcare
Latest close
As of 29 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 777K
- P/E ratio
- Not available
- Analyst target
- 5.32
- Dividend yield
- Not available
- Beta
- 0.9
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- DE000A37FT41
- Market cap
- 777K
- P/E ratio
- Not available
- Analyst target
- 5.32
- Dividend yield
- Not available
- Beta
- 0.9
About
About Epigenomics AG
Epigenomics AG does not have significant operations. Previously, the company was involved in liquid biopsy for the early detection of cancer. Epigenomics AG was founded in 1998 and is headquartered in Heidelberg, Germany.
Research context
Epigenomics AG appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Diagnostics & Research
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ECX.F discussion.
5 years, 7 months ago
Epigenomics AG is currently in a long term downtrend where the price is trading 35.1% below its 200 day moving average.
From a valuation standpoint, the stock is 98.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 15.5.
Epigenomics AG's total revenue rose by 8.3% to $301K since the same quarter in the previous year.
Its net income has increased by 63.2% to $-3M since the same quarter in the previous year.
Finally, its free cash flow grew by 22.4% to $-2M since the same quarter in the previous year.
Based on the above factors, Epigenomics AG gets an overall score of 4/5.